| Literature DB >> 29556273 |
Deng-Xing Lun1,2,3, Yong-Cheng Hu3, Xiong-Gang Yang3, Feng Wang3, Zhao-Wan Xu2.
Abstract
Reconstruction of bone defects following femoral diaphyseal tumor resection is challenging. Segmental allograft (SA) and intercalary prosthesis (IP) are the most common reconstruction methods for femoral diaphyseal metastatic tumors with pathological fracture. However, whether the complications and functional outcomes differ between SA and IP remains unclear. To compare the clinical outcomes and complications for patients treated with SA reconstruction or IP replacement for femoral shaft tumors, 34 patients who had undergone intercalary resection for metastatic tumor with pathological fracture in the femoral diaphysis were evaluated. Of these, 18 had received SA and 16 IP. There were 11 males, and 24 females, with a mean age of 64.5±11.3 years. The most common sites of primary metastases were lung (26.5%), breast (17.6%) and liver (14.7%). The visual analog scale (VAS), implant-related complications and the Musculoskeletal Tumor Society (MSTS) scores for each patient were collected. The follow-up period for patients ranged from 2 to 27 months. At the most recent follow-up, 28 patients had succumbed to mortality, with a mean survival time of 6.9±3.7 months for the IP group and 7.4±3.0 months for the SA group. Patients with IP had a significantly shorter time to full weight bearing and hospitalization time than those who received SA (P=0.003 and P=0.002, respectively). The rates of overall complications and implant-related complications were significantly lower for IP as compared with SA (18.8 vs. 66.7%, P=0.007; 12.5 vs. 55.6%, P=0.013). The reoperation rate of the SA group was higher than that of the IP group (38.9 vs. 12.5%), however the difference between the two groups was statistically insignificant (P=0.125). MSTS scores were significantly higher for the IP group as compared with the SA group at one month after surgery (IP, 26.7±1.6 vs. SA, 20.3±1.5; P<0.05), without a significant difference at the final follow-up. There were no statistically significant differences in age, sex, length of resection, follow-up time, operative time or blood loss between the two groups. In summary, IP reconstruction may provide improved early functional outcomes and fewer early complications, particularly for patients with a shorter life expectancy due to femoral metastatic tumors with pathological fracture.Entities:
Keywords: intercalary prosthesis; metastatic tumor; pathological fracture; segmental allograft
Year: 2018 PMID: 29556273 PMCID: PMC5844073 DOI: 10.3892/ol.2018.7804
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Comparative data variables between the IP and SA groups.
| Categories | IP | SA | P-value |
|---|---|---|---|
| Total | 16 | 18 | |
| No. of females, % | 62.5 | 72.2 | 0.717 |
| Clinical characteristics, mean ± SD | |||
| Age, years | 64.5±11.4 | 64.1±11.5 | 0.922 |
| Defect size, mm | 101.9±26.1 | 100.0±31.12 | 0.851 |
| Operative time, min | 105.3±24.6 | 114.7±25.3 | 0.281 |
| Blood loss, ml | 715.6±342.4 | 1,319.4±1,700.5 | 0.064 |
| Hospitalization time, days | 8.9±3.8 | 12.3±6.7 | 0.002 |
| Survival time, months | 6.9±3.7 | 7.4±3.0 | 0.763 |
| Time to full-weight bearing, months | 79.0±12.0 | 103.4±24.2 | 0.003 |
| Follow-up time, months | 9.0±6.8 | 12.4±6.7 | 0.086 |
| Complications, n (%) | |||
| Total | 3 (18.8) | 12 (66.7) | 0.007 |
| Loosening[ | 1 (6.3) | – | – |
| Fracture | 0 (0) | 3 (16.7) | 0.230 |
| Peri-prosthetic fracture[ | 1 (6.3) | – | – |
| Infection | 1 (6.3) | 5 (27.8) | 0.180 |
| Local recurrence | 1 (6.3) | 1 (5.6) | – |
| Nonunion[ | – | 7 (38.9) | – |
| Implant-related | 2 (12.5) | 10 (55.6) | 0.013 |
| Reoperation rate | 2 (12.5) | 7 (38.9) | 0.125 |
| MSTS score, mean ± SD | |||
| Postoperative (1 month) | 26.7±1.6 | 20.3±1.5 | <0.001 |
| Postoperative (last follow-up) | 27.1±1.7 | 26.9±1.6 | 0.986 |
| Visual analog scale score, mean ± SD | |||
| Preoperative | 8.7±0.7 | 8.6±0.8 | 0.642 |
| Postoperative (1 day) | 2.2±0.9 | 2.4±1.0 | 0.527 |
| Postoperative (last follow-up)[ | – | – | – |
The group sizes were too small to be statistically analyzed. IP, intercalary prosthesis; SA, segmental allograft; SD, standard deviation; MSTS, musculoskeletal tumor society.
Figure 1.Segmental allograft process. (A) Anteroposterior radiograph of a left femur exhibiting diaphyseal pathological fracture due to metastatic tumors. (B) Intraoperative photograph demonstrating the position of the allograft. (C) Post-operative anteroposterior radiograph of the allograft reconstruction.
Figure 2.Intercalary prosthesis process. (A) Anteroposterior radiograph of a right femur exhibiting diaphyseal pathological fracture due to metastatic tumors. (B) Intraoperative photograph demonstrating the position of the prosthesis. (C) Post-operative anteroposterior radiograph of the distal prosthesis. (D) Post-operative anteroposterior radiograph of the proximal prosthesis.
Figure 3.Schematic diagram of the surgical procedure for an intercalary prosthesis.
Figure 4.Kaplan-Meier survival curves for (A) implants (P=0.127) and (B) patients (P=0.778) stratified by IP and SA treatment groups. IP, intercalary prosthesis; SA, segmental allograft.
Characteristics of the patients in the segmental allograft group.
| Visual analog scale score | MSTS score | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Age, years | Sex | Diagnosis | Resection length, mm | Follow-up, months | Status | FW, weeks | HT, days | Blood loss, ml | Operative time, min | Complications | Preoperative | 1 day | Last follow-up | 1 month | Last follow-up |
| 1 | 48 | F | TC | 95 | 20 | A | 120 | 14 | 1,200 | 140 | 10 | 3 | 1 | 21 | 25 | |
| 2 | 67 | F | CC | 85 | 3 | D | – | 10 | 900 | 100 | 8 | 2 | – | 20 | 26 | |
| 3 | 71 | M | LIC | 105 | 7 | D | 100 | 16 | 1,150 | 85 | NU (4 months) | 9 | 3 | – | 19 | 26 |
| 4 | 42 | F | LC | 120 | 21 | A | 120 | 18 | 1,000 | 110 | NU, IF (4 months) | 10 | 4 | 1 | 19 | 22 |
| 5 | 81 | F | RC | 160 | 28 | A | 110 | 20 | 8,000 | 110 | NU (6 months) | 8 | 1 | 1 | 19 | 27 |
| 6 | 72 | M | LC | 90 | 10 | D | 89 | 9 | 700 | 120 | RE (7 months) | 9 | 2 | – | 20 | 26 |
| 7 | 67 | F | CC | 70 | 6 | D | 76 | 10 | 600 | 120 | 7 | 3 | – | 21 | 25 | |
| 8 | 77 | F | LC | 100 | 7 | D | 92 | 11 | 350 | 130 | IF (1 month) | 9 | 3 | – | 18 | 26 |
| 9 | 56 | F | BC | 80 | 14 | D | 67 | 12 | 1,550 | 130 | 9 | 1 | – | 20 | 25 | |
| 10 | 67 | M | RC | 125 | 12 | A | 88 | 10 | 900 | 90 | FC (8 months) | 8 | 1 | 1 | 20 | 25 |
| 11 | 65 | F | BC | 40 | 6 | D | 89 | 18 | 550 | 95 | FC, IF (1 months) | 9 | 3 | – | 21 | 25 |
| 12 | 79 | F | LC | 70 | 7 | D | 82 | 14 | 600 | 100 | NU, IF (4 months) | 8 | 2 | – | 22 | 25 |
| 13 | 57 | F | LC | 170 | 9 | D | 97 | 9 | 1,000 | 110 | IF (10 days) | 9 | 4 | – | 23 | 25 |
| 14 | 61 | M | PC | 85 | 10 | D | 167 | 10 | 950 | 160 | NU, FC (7 months) | 8 | 3 | – | 21 | 25 |
| 15 | 47 | F | LIC | 95 | 7 | D | 118 | 7 | 1,000 | 150 | NU (6 months) | 9 | 2 | – | 18 | 26 |
| 16 | 62 | M | PC | 90 | 6 | D | 122 | 14 | 1,700 | 155 | NU (5 months) | 8 | 3 | – | 20 | 25 |
| 17 | 79 | F | BC | 120 | 10 | D | 117 | 9 | 750 | 75 | 8 | 2 | – | 22 | 28 | |
| 18 | 56 | F | GC | 100 | 2 | D | – | 11 | 850 | 85 | 9 | 1 | – | 23 | 29 | |
FW, time to full weight bearing; HT, hospitalization time; MSTS, musculoskeletal tumor society; TC, thyroid cancer; CC, cervical cancer; LIC, liver cancer; LC, lung cancer; RC, renal cancer; BC, breast cancer; PC, prostate cancer; GC, gastric cancer; A, alive; D, deceased; NU, nonunion; IF, infection; RE, recurrence; FC, fracture.
Characteristics of the patients in the intercalary prostheses group.
| Visual analog scale score | MSTS score | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Age, years | Sex | Diagnosis | Resection length, mm | Follow-up, months | Status | FW, weeks | HT, days | Blood loss, ml | Operative time, min | Complications | Preoperative | 1-day | Last follow-up | 1-month | Last follow-up |
| 1 | 58 | M | LC | 80 | 4 | D | 89 | 8 | 1,200 | 120 | 9 | 2 | – | 26 | 26 | |
| 2 | 74 | F | GC | 90 | 2 | D | – | 10 | 1,000 | 100 | 8 | 3 | – | 26 | 27 | |
| 3 | 57 | F | LIC | 110 | 4 | D | 90 | 9 | 600 | 110 | 9 | 2 | – | 26 | 26 | |
| 4 | 31 | F | LIC | 110 | 25 | A | 98 | 12 | 1,050 | 90 | PPF (4 months) | 8 | 1 | 0 | 22 | 24 |
| 5 | 57 | F | BC | 160 | 23 | A | 87 | 7 | 750 | 80 | 9 | 2 | 1 | 26 | 26 | |
| 6 | 80 | F | CC | 90 | 8 | D | 70 | 10 | 850 | 60 | ASL, RE (7 months) | 9 | 3 | – | 28 | 29 |
| 7 | 64 | F | RC | 80 | 9 | D | 65 | 10 | 350 | 150 | 10 | 1 | – | 27 | 28 | |
| 8 | 68 | F | LC | 120 | 10 | D | 91 | 21 | 850 | 110 | IF (6 months) | 9 | 1 | – | 26 | 26 |
| 9 | 60 | M | RC | 80 | 14 | D | 60 | 8 | 500 | 100 | 8 | 1 | – | 27 | 27 | |
| 10 | 63 | F | BC | 80 | 7 | D | 71 | 7 | 200 | 95 | 9 | 3 | – | 29 | 30 | |
| 11 | 65 | F | LIV | 80 | 4 | D | 68 | 9 | 200 | 90 | 8 | 2 | – | 27 | 30 | |
| 12 | 64 | M | LC | 100 | 9 | D | 80 | 6 | 750 | 100 | 9 | 4 | – | 27 | 26 | |
| 13 | 68 | M | LC | 110 | 2 | D | – | 7 | 1,400 | 160 | 8 | 3 | – | 27 | 27 | |
| 14 | 74 | M | PC | 120 | 10 | D | 80 | 8 | 750 | 120 | 9 | 2 | – | 25 | 25 | |
| 15 | 76 | M | TC | 70 | 3 | D | 67 | 4 | 450 | 110 | 8 | 3 | – | 27 | 27 | |
| 16 | 73 | F | BC | 150 | 10 | D | 90 | 6 | 550 | 90 | 10 | 2 | – | 29 | 29 | |
FW, time to full weight bearing; HT, hospitalization time; MSTS, Musculoskeletal Tumor Society; LC, lung cancer; GC, gastric cancer; LIC, liver cancer; TC, thyroid cancer; RC, renal cancer; BC, breast cancer; PC, prostate cancer; A, alive; D, deceased; PPF, peri-prosthetic fractures; ASL, aseptic loosening; RE, recurrence; IF, infection.